Swati Patolia1, Getahun Abate2, Nirav Patel2, Setu Patolia3, Sharon Frey2. 1. Department of Infectious Disease, St. Anthony's Medical Center, 12700 Southfork Road, Suite 200, St Louis, MO 63128, USA. 2. Department of Infectious Disease, School of Medicine, Saint Louis University, St. Louis, MO, USA. 3. Division of Pulmonary, Critical Care and Sleep Medicine, School of Medicine, Saint Louis University, St. Louis, MO, USA.
Abstract
BACKGROUND: The incidence of multidrug-resistant (MDR) organisms is increasing along with mortality. Identifying risk factors for the development of MDR Gram-negative bacilli (GNB) bacteremia could greatly impact patient care and management. METHODS: Data from the electronic health record of patients with GNB over 13-month period were collected at a single university medical center. Baseline demographic data, risk factor, microbiological data, recurrence of bacteremia, and mortality were recorded. RESULTS: A total of 177 patients were included in the analysis. MDR GNB occurred in 46 patients (26%). The mortality rate in the MDR group was 34.8% compared to 13.7% in non-MDR group (p = 0.002). In multivariate analysis, diabetes mellitus [DM; odds ratio (OR): 2.8, 95% confidence interval (CI): 1-4.88], previous antibiotic use (OR: 2.93, 95% CI: 1.25-6.87), and urinary catheter as a source of infection (OR 5.96, 95% CI: 1.78-19.94) were significant risk factors for the development of MDR GNB. In addition, end-stage liver disease (OR: 3.64, 95% CI: 1.07-12.3), solid organ malignancy (OR: 3.64, 95% CI: 1.25-10.56), intra-abdominal source of infection (OR: 3.66, 95% CI: 1.14-11.73), inappropriate empiric antibiotics (OR 7.59, 95% CI: 1.68-34.34) and urinary catheter as a source of infection (OR 5.68, 95% CI: 1.37-23.5) were significant factors for mortality in patients with MDR GNB. CONCLUSION: Our study provides important information about the risk factors for the development of MDR GNB bacteremia and helps prognosticate patient with MDR GNB.
BACKGROUND: The incidence of multidrug-resistant (MDR) organisms is increasing along with mortality. Identifying risk factors for the development of MDR Gram-negative bacilli (GNB) bacteremia could greatly impact patient care and management. METHODS: Data from the electronic health record of patients with GNB over 13-month period were collected at a single university medical center. Baseline demographic data, risk factor, microbiological data, recurrence of bacteremia, and mortality were recorded. RESULTS: A total of 177 patients were included in the analysis. MDR GNB occurred in 46 patients (26%). The mortality rate in the MDR group was 34.8% compared to 13.7% in non-MDR group (p = 0.002). In multivariate analysis, diabetes mellitus [DM; odds ratio (OR): 2.8, 95% confidence interval (CI): 1-4.88], previous antibiotic use (OR: 2.93, 95% CI: 1.25-6.87), and urinary catheter as a source of infection (OR 5.96, 95% CI: 1.78-19.94) were significant risk factors for the development of MDR GNB. In addition, end-stage liver disease (OR: 3.64, 95% CI: 1.07-12.3), solid organ malignancy (OR: 3.64, 95% CI: 1.25-10.56), intra-abdominal source of infection (OR: 3.66, 95% CI: 1.14-11.73), inappropriate empiric antibiotics (OR 7.59, 95% CI: 1.68-34.34) and urinary catheter as a source of infection (OR 5.68, 95% CI: 1.37-23.5) were significant factors for mortality in patients with MDR GNB. CONCLUSION: Our study provides important information about the risk factors for the development of MDR GNB bacteremia and helps prognosticate patient with MDR GNB.
Authors: Argyris Michalopoulos; Matthew E Falagas; Dimitra C Karatza; Paraskevi Alexandropoulou; Emmanuel Papadakis; Leonidas Gregorakos; George Chalevelakis; Georgios Pappas Journal: Am J Infect Control Date: 2010-10-30 Impact factor: 2.918
Authors: Yohei Doi; Yoon Soo Park; Jesabel I Rivera; Jennifer M Adams-Haduch; Ameet Hingwe; Emilia M Sordillo; James S Lewis; Wanita J Howard; Laura E Johnson; Bruce Polsky; James H Jorgensen; Sandra S Richter; Kathleen A Shutt; David L Paterson Journal: Clin Infect Dis Date: 2012-11-13 Impact factor: 9.079
Authors: R Ben-Ami; M J Schwaber; S Navon-Venezia; D Schwartz; M Giladi; I Chmelnitsky; A Leavitt; Y Carmeli Journal: Clin Infect Dis Date: 2006-02-27 Impact factor: 9.079
Authors: Mariana Castanheira; Sarah E Farrell; Kevin M Krause; Ronald N Jones; Helio S Sader Journal: Antimicrob Agents Chemother Date: 2013-11-18 Impact factor: 5.191
Authors: Sarah Sabour; Jennifer Y Huang; Amelia Bhatnagar; Sarah E Gilbert; Maria Karlsson; David Lonsway; Joseph D Lutgring; J Kamile Rasheed; Alison Laufer Halpin; Richard A Stanton; Stephanie Gumbis; Christopher A Elkins; Allison C Brown Journal: Antimicrob Agents Chemother Date: 2021-09-27 Impact factor: 5.191
Authors: Roumayne L Ferreira; Brenda C M da Silva; Graziela S Rezende; Rafael Nakamura-Silva; André Pitondo-Silva; Emeline Boni Campanini; Márcia C A Brito; Eulália M L da Silva; Caio César de Melo Freire; Anderson F da Cunha; Maria-Cristina da Silva Pranchevicius Journal: Front Microbiol Date: 2019-01-22 Impact factor: 5.640
Authors: Selma Tobudic; Isabella Prager; Manuel Kussmann; Markus Obermüller; Martin Ursli; Markus Zeitlinger; Martin Wiesholzer; Heinz Burgmann; Wolfgang Poeppl; Gottfried Reznicek Journal: Sci Rep Date: 2020-02-04 Impact factor: 4.379
Authors: Aisha S Al Hamdan; Amal A Alghamdi; Ghada F Alyousif; Fatma A Hamza; Marwa M Shafey; Aisha M AlAmri; Abdulaziz A Sunki Journal: Infect Drug Resist Date: 2022-02-17 Impact factor: 4.003